BAY 87‐2243, a highly potent and selective inhibitor of hypoxia‐induced gene activation has antitumor activities by inhibition of mitochondrial complex I
Open Access
- 20 August 2013
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 2 (5), 611-624
- https://doi.org/10.1002/cam4.112
Abstract
The activation of the transcription factor hypoxia-inducible factor-1 (HIF-1) plays an essential role in tumor development, tumor progression, and resistance to chemo- and radiotherapy. In order to identify compounds targeting the HIF pathway, a small molecule library was screened using a luciferase-driven HIF-1 reporter cell line under hypoxia. The high-throughput screening led to the identification of a class of aminoalkyl-substituted compounds that inhibited hypoxia-induced HIF-1 target gene expression in human lung cancer cell lines at low nanomolar concentrations. Lead structure BAY 87-2243 was found to inhibit HIF-1α and HIF-2α protein accumulation under hypoxic conditions in non-small cell lung cancer (NSCLC) cell line H460 but had no effect on HIF-1α protein levels induced by the hypoxia mimetics desferrioxamine or cobalt chloride. BAY 87-2243 had no effect on HIF target gene expression levels in RCC4 cells lacking Von Hippel–Lindau (VHL) activity nor did the compound affect the activity of HIF prolyl hydroxylase-2. Antitumor activity of BAY 87-2243, suppression of HIF-1α protein levels, and reduction of HIF-1 target gene expression in vivo were demonstrated in a H460 xenograft model. BAY 87-2243 did not inhibit cell proliferation under standard conditions. However under glucose depletion, a condition favoring mitochondrial ATP generation as energy source, BAY 87-2243 inhibited cell proliferation in the nanomolar range. Further experiments revealed that BAY 87-2243 inhibits mitochondrial complex I activity but has no effect on complex III activity. Interference with mitochondrial function to reduce hypoxia-induced HIF-1 activity in tumors might be an interesting therapeutic approach to overcome chemo- and radiotherapy-resistance of hypoxic tumors.This publication has 40 references indexed in Scilit:
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012
- Targeting mitochondria as a therapeutic target in cancerJournal of Cellular Physiology, 2011
- Inhibition of HIF Prolyl Hydroxylase-2 Blocks Tumor Growth in Mice through the Antiproliferative Activity of TGFβCancer Research, 2011
- Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1α Expression in an AhR-Independent FashionCancer Research, 2010
- Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularizationProceedings of the National Academy of Sciences of the United States of America, 2009
- A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulationProceedings of the National Academy of Sciences of the United States of America, 2008
- Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1αMolecular Cancer Therapeutics, 2008
- Suppression of Hypoxia-inducible Factor 1α (HIF-1α) Transcriptional Activity by the HIF Prolyl Hydroxylase EGLN1Published by Elsevier BV ,2005
- Role of Hypoxia-Inducible Factor 1 in Gastric Cancer Cell Growth, Angiogenesis, and Vessel MaturationJNCI Journal of the National Cancer Institute, 2004
- Regulation of angiogenesis by hypoxia: role of the HIF systemNature Medicine, 2003